AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Anti-KLK8

Summary

Kallikrein-8 as an early biomarker for the prediction and diagnosis of Alzheimer`s disease – even of precursor stages long before clinical symptoms appear.

Technology Benefits

First-in-class therapy approach for AD
For the treatment and prevention of AD
Biomarker for predicting and diagnosing AD – even precursor stages of AD long before clinical symptoms appear
Molecular mode of action largely deciphered

Technology Application

KLK8 is a potential (early) biomarker for the diagnosis of for Alzheimer’s disease. Antibody-mediated inhibition of KLK8 is a promising therapeutic approach against for Alzheimer’s disease.

Detailed Technology Description

Four weeks of KLK8 inhibition in a moderate disease stage is sufficient to mitigate multiple features of Alzheimer’s pathology in mice without causing any adverse reactions. Cerebral KLK8 blockade reduces amyloid β (Aβ) pathology by impeding amyloidogenic amyloid-precursor-protein (APP) processing, facilitating Aβ clearance across the blood-brain-barrier and boosting microglial Aβ phagocytosis and autophagy, resulting in decreased Aβ plaque burden.
KLK8 inhibition further attenuates tau pathology by suppressing tau phosphorylation signaling and subsequent tau hyperphosphorylation.

Type of Cooperation

Licensing

Application Date

02/12/2016 00:00:00

Application No.

EP20160775537 20160921

Classes

- international:
A61K39/395; A61P25/28; C07K16/40; G01N33/53
- cooperative:
A61K39/395; A61P25/28; C07K16/40; A61K2039/505; A61K2039/54; A61K9/51; C07K2317/76

Others

Patent application

ID No.

4509

Country/Region

Germany

For more information, please click Here